Safety, Tolerability, Pharmacokinetics, & Pharmacodynamics of IONIS-MAPTRx

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease

Mild Alzheimer's Disease Clinical Trial

Official title:
A Randomized, Double-Blind, Placebo-Controlled Study, Followed by an Open-Label Extension, to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 814907 in Patients With Mild Alzheimer's Disease

Status Completed

Clinical Trial Summary

The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS-MAPTRx in patients with Mild Alzheimer's Disease

Clinical Trial Description

This is a randomized, double-blind, placebo-controlled study, followed by an Open-Label Extension in up to 44 participants. This study will consist in two parts: Part 1: a randomized, double-blind, placebo-controlled multiple ascending dose period in participants with Mild Alzheimer's Disease, followed by Part 2: the open-label, long-term extension period. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03186989
Study type	Interventional
Source	Ionis Pharmaceuticals, Inc.
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	October 12, 2017
Completion date	May 13, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00243451` - Early Detection of Mild Cognitive Impairment in Individual Patients	N/A
Recruiting	`NCT05872243` - pBFS Guided rTMS Treating Mild Alzheimer's Disease(AD)	N/A
Recruiting	`NCT05417555` - Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease	N/A
Terminated	`NCT01482013` - Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease	Phase 1
Not yet recruiting	`NCT03752294` - A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.	Phase 1
Completed	`NCT01013610` - An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease	Phase 1
Recruiting	`NCT06058234` - Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
Active, not recruiting	`NCT03234686` - Deferiprone to Delay Dementia (The 3D Study)	Phase 2
Completed	`NCT05233774` - Lomecel-B Effects on Alzheimer's Disease	Phase 2
Withdrawn	`NCT05032482` - WeArable Neuromodulation DeVice for the TrEatment of Alzheimer's Disease	N/A
Terminated	`NCT00582855` - Effect of AQW051 in Patients With Memory Impairment	Phase 2
Completed	`NCT01061489` - Sensory-cognitive and Physical Fitness Training in Mild Cognitive Impairment	N/A
Completed	`NCT01548287` - A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment	Phase 2
Terminated	`NCT00706186` - Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients	Phase 4